drugset / Trial / NCT00002733
Biological Therapy in Treating Patients With Metastatic Cancer
Treatment
Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with metastatic cancer.
Timeline
- Start
- 1996-01
- Primary completion
- 2000-01
- Completion
- 2000-01
Publications
- Background Dillman RO, Hurwitz SR, Schiltz PM, Barth NM, Beutel LD, Nayak SK, O'Connor AA. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer. Cancer Biother Radiopharm. 1997 Apr;12(2):65-71. doi: 10.1089/cbr.1997.12.65.
- Background Schiltz PM, Beutel LD, Nayak SK, Dillman RO. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J Immunother. 1997 Sep;20(5):377-86. doi: 10.1097/00002371-199709000-00007.
- Background Dillman RO, Hurwitz R, Schlitz PM, et al.: Radioimmunodetection of cancer with 111-Indium conjugated tumor infiltrating lymphocytes in patients with metastatic renal cell carcinoma. J Immunother 19(6): 457, 1996.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cimetidine | Small molecule | — | Oral |
| Subject | aldesleukin | Protein / enzyme biologic | — | Intravenous |
| Subject | recombinant interferon alfa | Protein / enzyme biologic | — | Subcutaneous |
| Subject | therapeutic tumor infiltrating lymphocytes | Cell therapy | — | — |